fig1
![Treatment of unresectable malignant pleural mesothelioma in 2021: emerging standards in immunotherapy](https://image.oaes.cc/05729baa-4663-4b48-ab15-d08540c196df/4242.fig.1.jpg)
Figure 1. Results from CheckMate 743: first-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma. Overall survival in all randomised patients (A) and in patients with epithelioid tumour histology (B) and non-epithelioid tumour histology (C). The hazard ratio in part A is stratified by sex and histology. The hazard ratios in parts B and C are from unstratified Cox proportional hazard models. This figure is quoted with permission from Baas et al.[10].